Table 1.
Baseline characteristics
| Demographics | N (%) | |
|---|---|---|
| Age | Median = 58 (30–88) | |
| Male, female | 26/70 (37%), 44/70 (63%) | |
| Median treatment cycles (min-max) | 1 (1–5) | |
| Therapy | ||
| Chemoradiation | 16/69 (23%) | |
| Chemotherapy alone | 53/69 (77%) | |
| Chemotherapy | ||
| 5-fluorouracil | 42/70 (60%) | |
| 5-fluorouracil and irinotecan | 8/70 (11%) | |
| Capecitabine | 12/70 (17%) | |
| Erlotinib | 4/70 (6%) | |
| Gefitinib | 3/70 (4%) | |
| Afatinib | 1/70 (1%) | |
| Ethnicity | ||
| North American | 26/70 (37%) | |
| European | 22/70 (31%) | |
| African | 4/70 (6%) | |
| Asian | 18/70 (26%) | |
| Cancer site | ||
| Colorectal | 26/72 (38%) | |
| Breast | 17/72 (24%) | |
| Lung | 8/72 (11%) | |
| Pancreatic | 6/72 (8%) | |
| Anal | 5/72 (7%) | |
| Gastric | 4/72 (6%) | |
| Appendix | 1/72 (1%) | |
| Endometrial | 1/72 (1%) | |
| Esophageal | 1/72 (1%) | |
| Melanoma | 1/72 (1%) | |
| Vulva | 1/72 (1%) | |
| Educational level | ||
| Post-secondary | 47/69 (68%) | |
| Secondary | 16/69 (23%) | |
| Doctorate | 3/69 (4%) | |
| Primary | 2/69 (3%) | |
| Post-graduate | 1/69 (2%) | |